Revive Therapeutics and South Carolina Research Foundation Enter into Exclusive License Agreement for Cannabinoids-Based Therapeutics in the Treatment of Liver Diseases
TORONTO, ONTARIO--(Sept. 19, 2017) - Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced that it has entered into a license agreement with South Carolina Research Foundation ("SCRF"), under which Revive will acquire an exclusive license from SCRF to develop and commercialize a portfolio of patents based on cannabinoid-based therapeutics, such as Cannabidiol, in the treatment of liver diseases.
- Category: Biotech
- Published: 19 September 2017
- Written by Editor